Email the author Irisin as a Biomarker for Insulin Resistance in Polycystic Ovary Syndrome: a Meta-analysis
Abstract
Background: Irisin has attracted growing interest as a potential novel biomarker of polycystic ovary syndrome (PCOS). Aim: A meta-analysis was performed to compare circulating irisin concentrations between PCOS and control women, and to explore the possible relation of irisin and insulin resistance, by associating this hormone with the homeostatic model assessment for insulin resistance (HOMA-IR). Methods: An extended search of the PubMed/Medline, Google Scholar, and Web of Science databases (last updated on 9 March 2019) was performed to identify all articles published in the English language pertaining to circulating irisin in women with PCOS and control women. Results: Eleven studies that involved 1,017 PCOS patients and 669 controls were included. A random effects model revealed a moderate estimate of effect size (SMD: 0.27, 95% CI: -0.13 to 0.67), indicating that circulating irisin concentrations did not differ significantly between PCOS women and controls. Another random effects model (four studies) revealed a moderate estimate of correlation and a statistically significant positive correlation between circulating irisin concentrations and HOMA-IR (Correlation: 0.372, 95% CI: 0.0843 to 0.603, p = 0.012). Irisin may play an important role in PCOS in relation to the inherent insulin resistance of the syndrome. This association requires further clarification in well-designed large-scale studies in women with PCOS.
Keywords
References
Abali R, Temel Yuksel I, Yuksel MA, Bulut B, Imamoglu M, Emirdar V, Unal F, Guzel S & Celik C 2016 Implications of circulating irisin and Fabp4 levels in patients with polycystic ovary syndrome. J Obstet Gynaecol 36 897-901
Adamska A, Karczewska-Kupczewska M, Lebkowska A, Milewski R, Górska M, Otziomek E, Nikolajuk A, Wolczynski S & Kowalska I 2016 Serum irisin and its regulation by hyperinsulinemia in women with polycystic ovary syndrome. Endocr J 63 1107-1112
Amato MC, Vesco R, Vigneri E, Ciresi A & Giordano C 2015 Hyperinsulinism and polycystic ovary syndrome (PCOS): role of insulin clearance. J Endocrinol Invest 38 1319-1326
Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF, Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society 2009 The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 91 456-488
Bacopoulou F, Athanasopoulos N, Efthymiou V, Mantzou A, Aravantinos L, Vlahopoulos S & Deligeoroglou E 2018 Serum irisin concentrations in lean adolescents with polycystic ovary syndrome. Clin Endocrinol (Oxf) 88 585-591
Bostancı MS, Akdemir N, Cinemre B, Cevrioglu AS, Özden S & Ünal O 2015 Serum irisin levels in patients with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci 19 4462-4468
Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Boström EA, Choi JH, Long JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Højlund K, Gygi SP & Spiegelman BM 2012 A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481 463-468
Cai X, Qiu S, Li L, Zügel M, Steinacker JM & Schumann U 2018 Circulating irisin in patients with polycystic ovary syndrome: a meta-analysis. Reprod Biomed Online 36 172-180
Chang CL, Huang SY, Soong YK, Cheng PJ, Wang CJ & Liang IT 2014 Circulating irisin and glucose-dependent insulinotropic peptide are associated with the development of polycystic ovary syndrome. J Clin Endocrinol Metab 99 E2539-2548
Ducluzeau PH, Cousin P, Malvoisin E, Bornet H, Vidal H, Laville M & Pugeat M 2003 Glucose-to-insulin ratio rather than sex hormone binding globulin and adiponectin levels is the best predictor of insulin resistance in nonobese women with polycystic ovary syndrome. J Clin Endocrinol Metab 88 3626-3631
Dunaif A, Segal KR, Futterweit W & Dobrjansky A 1989 Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38 1165-1174
Gao S, Cheng Y, Zhao L, Chen Y & Liu Y 2016 The relationships of irisin with bone mineral density and body composition in PCOS patients. Diabetes Metab Res Rev 32 421-428
Gungor N, Saad R, Janosky J & Arslanian S 2004 Validation of surrogate estimates of insulin sensitivity and insulin secretion in children and adolescents. J Pediatr 144 47-55
Higgins JPT, Green S, Cochrane Collaboration 2008 Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Book Series. Wiley-Blackwell, Chichester, England; Hoboken, NJ
Ibáñez L, Oberfield SE, Witchel S, Auchus RJ, Chang RJ, Codner E, Dabadghao P, Darendeliler F, Elbarbary NS, Gambineri A, Garcia Rudaz C, Hoeger KM, López-Bermejo A, Ong K, Peña AS, Reinehr T, Santoro N, Tena-Sempere M, Tao R, Yildiz BO, Alkhayyat H, Deeb A, Joel D, Horikawa R, de Zegher F & Lee PA 2017 An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence. Horm Res Paediatr 88 371-395
Kandaraki E, Chatzigeorgiou A, Livadas S, Palioura E, Economou F, Koutsilieris M, Palimeri S, Panidis D & Diamanti-Kandarakis E 2011 Endocrine disruptors and polycystic ovary syndrome (PCOS): elevated serum levels of bisphenol A in women with PCOS. J Clin Endocrinol Metab 96 E480-E484
Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK; Endocrine Society 2013 Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 98 4565-4592
Legro RS, Kunselman AR, Dodson WC & Dunaif A 1999 Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84 165-169
Lewy VD, Danadian K, Witchel SF & Arslanian S 2001 Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr 138 38-44
Li H, Xu X, Wang X, Liao X, Li L, Yang G & Gao L 2016 Free androgen index and Irisin in polycystic ovary syndrome. J Endocrinol Invest 39 549-556
Li M, Yang M, Zhou X, Fang X, Hu W, Zhu W, Wang C, Liu D, Li S, Liu H, Yang G & Li L 2015 Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome. J Clin Endocrinol Metab 100 1485-1493
Liu JJ, Wong MD, Toy WC, Tan CS, Liu S, Ng XW, Tavintharan S, Sum CF & Lim SC 2013 Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications 27 365-369
Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L & Azziz R 2016 Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril 106 6-15
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC 1985 Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 412-419
Moher D, Liberati A, Tetzlaff J, Altman DG & PRISMA Group 2010 Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8 336-341
Park KH, Zaichenko L, Brinkoetter M, Thakkar B, Sahin-Efe A, Joung KE, Tsoukas MA, Geladari EV, Huh JY, Dincer F, Davis CR, Crowell JA & Mantzoros CS 2013 Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab 98 4899-4907
Polak K, Czyzyk A, Simoncini T & Meczekalski B 2017 New markers of insulin resistance in polycystic ovary syndrome. J Endocrinol Invest 40 1-8
Polyzos SA, Kountouras J, Shields K & Mantzoros CS 2013 Irisin: a renaissance in metabolism? Metabolism 62 1037-1044
Pukajło K, Łaczmański Ł, Kolackov K, Kuliczkowska-Płaksej J, Bolanowski M, Milewicz A & Daroszewski J 2015 Irisin plasma concentration in PCOS and healthy subjects is related to body fat content and android fat distribution. Gynecol Endocrinol 31 907-911
Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW & Nestler JE 2007 Glucose intolerance in polycystic ovary syndrome-A position statement of the Androgen Excess Society. J Clin Endocrinol Metab 92 4546-4556
Sesti G, Andreozzi F, Fiorentino TV, Mannino GC, Sciacqua A, Marini MA & Perticone F 2014 High circulating irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects. Acta Diabetol 51 705-713
Spritzer PM 2014 Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances. Arq Bras Endocrinol Metabol 58 182-187
Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P & Klapp BF 2013 Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity–correlation with body mass index. Peptides 39 125-130
Tate AR 2018 Type 2 diabetes. Lancet 391 1261-1262
Wang C, Zhang XY, Sun Y, Hou XG & Chen L 2018 Higher circulating irisin levels in patients with polycystic ovary syndrome: a meta-analysis. Gynecol Endocrinol 34 290-293
Wang W, Guo Y, Zhang X, Zheng J 2018 Abnormal irisin level in serum and endometrium is associated with metabolic dysfunction in polycystic ovary syndrome patients. Clin Endocrinol (Oxf) 89 474-480
Witchel SF, Oberfield S, Rosenfield RL, Codner E, Bonny A, Ibáñez L, Pena A, Horikawa R, Gomez-Lobo V, Joel D, Tfayli H, Arslanian S, Dabadghao P, Garcia Rudaz C & Lee PA 2015 The diagnosis of polycystic ovary syndrome during adolescence. Horm Res Paediatr 83 376-389
Zhang L, Fang X, Li L, Liu R, Zhang C, Liu H, Tan M & Yang G 2018 The association between circulating irisin levels and different phenotypes of polycystic ovary syndrome. J Endocrinol Invest 41 1401-1407
Zhang Y, Li R, Meng Y, Li S, Donelan W, Zhao Y, Qi L, Zhang M, Wang X, Cui T, Yang LJ & Tang D 2014 Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling. Diabetes 63 514-525
Refbacks
- There are currently no refbacks.
Copyright © 2021 Journal of Molecular Biochemistry